Nardin Lab - Microbiology

Elizabeth Nardin, Ph.D.
Professor, Department of Microbiology (Parasitology)


Old Public Health Building, Rm 408, Lab Rm 407
341 East 25th Street, New York, NY 10010
Office: (212) 263-8116
Lab: (212) 263-8194
Email: Elizabeth.Nardin@nyumc.org

 

 

KEY INTERESTS:

Malaria, vaccines, CD4+ T cells, humoral immunity, adjuvants and innate immunity, epitope identification, effector immune mechanisms in humans and murine models 

BIOGRAPHIC DETAILS:

Graduate Education:

Ph.D. Parasitology in 1979, New York University,
Department of Medical and Molecular Parasitology. 

Postdoctoral Training:

1982, Immunology, Department of Pathology,
New York University School of Medicine

Academic Appointments:

Assistant Professor 1985-1991 and Associate Professor 1992 -2009
Department of Medical and Molecular Parasitology;

Professor 2010, Department of Microbiology, Division of Medical Parasitology,
New York University School of Medicine

 

RESEARCH INTERESTS:

The main focus of our lab is to investigate mechanisms of innate and adaptive immunity to malaria parasites and to use these studies to advance the design of malaria vaccines and novel adjuvants. Vaccines are needed to prevent the 200 million infections, and over one million deaths, caused by the Plasmodium parasite each year. My laboratory studies the human immune responses elicited by attenuated parasites and subunit vaccines in an effort to identify relevant T- and B-cell epitopes for inclusion in vaccines. In recent clinical trials, we have tested safety and efficacy of synthetic peptide and virus-like particles (VLP) subunit vaccines that elicit synergistic humoral and cellular immunity to target both the extracellular and the intracellular parasite stages. In addition, we have developed transgenic rodent parasites expressing P. falciparum epitopes to provide a small animal model to explore new adjuvants and vaccine delivery platforms in vivo.  The goal of our research is develop cost-effective, subunit vaccines for the 40% of the world’s population currently at risk of malaria.

 

PUBLICATIONS:

The past decade of clinical trials of synthetic peptide malaria vaccines.
Nardin, E.
Human Vaccines.  (2011) 6(1):27-38.
PMID: 20173408

Enhanced immunogenicity of P. falciparum peptide vaccines using a topical adjuvant containing a potent synthetic TLR 7 agonist, imiquimod.
Othoro, C., Johnston, D., Lee, R., Soverow, J., Bystryn, J-C., and Nardin, E.
Infection and Immunity  2009;  77:739-48
PMID: 19047411

Imaging effector functions of human cytotoxic CD4+ T cells specific for P. falciparum circumsporozoite protein.
Frevert U, Moreno A, Calvo-Calle,JM, Klotz C, Nardin E.
International Journal of Parasitology  2009; 39:119-32.
PubMed Link: 18723023